GO:0050840 extracellular matrix binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0050840 extracellular matrix binding is a molecular function defined as binding to a component of the extracellular matrix.
• Key ECM-binding proteins include fibronectin, biglycan, and apolipoprotein E, which interact with matrix components to regulate cell adhesion, migration, and tissue homeostasis.
• Calcium ions are critical cofactors that modulate ECM protein interactions and structural integrity.
• Dysregulated ECM binding contributes to cancer progression, osteoarthritis, and cardiovascular disease.
• CRISPR knockout, knock-in, and overexpression models enable functional dissection of ECM-binding domains and their roles in disease.
• High-throughput screening and bioinformatics can identify novel ECM-binding proteins and their interaction networks.
Description
The extracellular matrix (ECM) is a complex network of proteins and polysaccharides that provides structural support and biochemical cues to cells. The molecular function of extracellular matrix binding (GO:0050840) refers to the ability of a protein or molecule to selectively interact with one or more ECM components. This binding is fundamental to numerous biological processes, including cell adhesion, migration, proliferation, and differentiation, and it is mediated by specific domains such as fibronectin type III repeats, calcium-binding motifs, and glycosaminoglycan-binding sites. Understanding ECM binding is crucial for researchers studying tissue development, wound healing, and disease pathogenesis, as disruptions in these interactions are linked to cancer, fibrosis, and degenerative conditions. This article synthesizes current knowledge on the mechanisms, key genes, and research methodologies associated with GO:0050840, providing a resource for experimental design and therapeutic targeting.
extracellular matrix binding At A Glance
| GO ID | GO:0050840 |
|---|---|
| GO term | extracellular matrix binding |
| Ontology | molecular_function |
| Synonym | adhesive extracellular matrix constituent; extracellular matrix constituent binding |
| Major function | Binding to a component of the extracellular matrix |
| Cofactors | Calcium ions often required for structural stabilization and binding affinity |
| Key domains | Fibronectin type III, EGF-like, calcium-binding EGF-like, and glycosaminoglycan-binding domains |
| Related processes | Cell adhesion, migration, wound healing, tissue remodeling |
| Disease relevance | Cancer metastasis, osteoarthritis, cardiovascular disease |
What Is GO:0050840?
According to the Gene Ontology, extracellular matrix binding (GO:0050840) is a molecular function defined as binding to a component of the extracellular matrix. This includes interactions with structural proteins such as collagens, fibronectin, and laminins, as well as proteoglycans and glycosaminoglycans. The term encompasses both direct binding to matrix proteins and binding to matrix-associated molecules, and it is often mediated by specific structural domains that recognize sequence motifs or post-translational modifications on ECM components.
Why Is extracellular matrix binding Important in Cell Biology?
Extracellular matrix binding is essential for maintaining tissue architecture and regulating cell behavior. It governs how cells sense and respond to their microenvironment, influencing processes such as proliferation, survival, and differentiation. Dysregulation of ECM binding is a hallmark of many diseases, including cancer, where altered interactions promote invasion and metastasis, and osteoarthritis, where matrix degradation leads to joint destruction. Moreover, ECM-binding proteins are attractive therapeutic targets and biomarkers, making this GO term highly relevant for both basic research and clinical translation.
• Mediates cell adhesion and migration by anchoring cells to the ECM.
• Regulates growth factor signaling by sequestering or presenting cytokines.
• Involved in tissue morphogenesis and wound healing.
• Dysregulated in cancer, promoting metastasis and drug resistance.
• Contributes to osteoarthritis through matrix degradation and inflammation.
• Modulates immune responses by binding to interferon-gamma.
• Affects cardiovascular health via apolipoprotein E and biglycan interactions.
• Target for bacterial adhesion, as seen in Staphylococcus epidermidis.
• Calcium-dependent binding is critical for structural integrity of ECM proteins.
• Provides potential biomarkers for disease diagnosis and prognosis.
What Happens During extracellular matrix binding?
Recognition and Initial Contact
In simple terms: The binding protein first recognizes and attaches to a specific site on an ECM molecule.
Extracellular matrix binding begins with the recognition of specific structural motifs on ECM components, such as the RGD sequence in fibronectin or glycosaminoglycan chains on proteoglycans. This recognition is often mediated by specialized domains like fibronectin type III repeats or calcium-binding EGF-like domains. For example, apolipoprotein E binds to the protein core of biglycan, a interaction that may retain apolipoprotein E in the vascular matrix. Similarly, Staphylococcus epidermidis expresses a giant extracellular matrix binding protein that binds surface-immobilized fibronectin via a novel mechanism.
Calcium-Dependent Conformational Changes
In simple terms: Calcium ions help the binding protein fold correctly and strengthen the interaction.
Many ECM-binding proteins require calcium ions for proper folding and binding activity. Calcium binding induces conformational changes that expose or stabilize binding interfaces, as seen in various extracellular matrix proteins. The presence of calcium can also modulate the affinity and specificity of interactions, as reviewed in the context of cell-ECM interactions. This calcium dependence is a common feature of ECM-binding domains and is critical for their function.
Stabilization of the Complex
In simple terms: Once bound, additional interactions stabilize the protein-ECM complex.
After initial binding, multiple non-covalent interactions, including hydrogen bonds, electrostatic interactions, and hydrophobic effects, stabilize the complex. For instance, fibronectin assembly involves interactions between fibronectin molecules and cell surface receptors, leading to fibril formation. The binding of interferon-gamma to the extracellular matrix prevents fatal systemic toxicity by sequestering the cytokine, highlighting the physiological importance of stable complex formation.
Functional Consequences
In simple terms: The binding event triggers downstream effects inside the cell.
Extracellular matrix binding can initiate intracellular signaling cascades that regulate cell behavior. For example, binding of ECM proteins to integrins activates focal adhesion kinase and downstream pathways controlling proliferation and migration. In osteoarthritis, targeting VGLL4 maintains extracellular matrix homeostasis, suggesting that ECM binding and downstream signaling are tightly linked. In cancer, remodeling of the tumor microenvironment by ECM protein 1a differentially regulates ovarian cancer metastasis, demonstrating that ECM binding can have context-dependent effects.
Key Genes Involved in GO:0050840 extracellular matrix binding
The following genes encode proteins that directly bind to extracellular matrix components and are frequently studied in the context of GO:0050840.
| Gene | Major Role | Research Relevance |
|---|---|---|
| FN1 | Fibronectin, a major ECM glycoprotein that binds integrins and other matrix molecules | Central to cell adhesion, migration, and matrix assembly; widely used as a model for ECM binding studies |
| BGN | Biglycan, a small leucine-rich proteoglycan that binds to collagen and growth factors | Involved in vascular matrix retention of apolipoprotein E and atherosclerosis |
| APOE | Apolipoprotein E, binds to biglycan and other ECM components | Implicated in cardiovascular disease and Alzheimer's disease; ECM binding affects its retention and function |
| SPP1 | Osteopontin, a secreted ECM protein that binds integrins and calcium | Regulates bone remodeling, immune responses, and cancer progression |
| COL1A1 | Type I collagen, the most abundant ECM protein | Provides structural support; mutations cause osteogenesis imperfecta |
| COL4A1 | Type IV collagen, a major component of basement membranes | Critical for tissue integrity; involved in vascular and renal diseases |
| LAMA1 | Laminin subunit alpha-1, a basement membrane protein | Regulates cell adhesion and differentiation; studied in development and cancer |
| LAMB1 | Laminin subunit beta-1, forms heterotrimers with other laminin chains | Important for basement membrane assembly and signaling |
| VTN | Vitronectin, binds integrins and proteoglycans | Involved in wound healing and cancer metastasis |
| THBS1 | Thrombospondin-1, a matricellular protein that binds many ECM components | Regulates angiogenesis and tumor progression |
| MMP2 | Matrix metalloproteinase-2, degrades ECM components | Its ECM binding and activity are linked to cancer invasion and osteoarthritis |
| MMP9 | Matrix metalloproteinase-9, degrades denatured collagen | Plays a role in inflammation and tissue remodeling |
| ITGB1 | Integrin beta-1, a cell surface receptor for ECM proteins | Mediates cell-ECM adhesion and signaling; knockout is lethal |
| ITGA5 | Integrin alpha-5, binds fibronectin | Critical for fibronectin fibrillogenesis and cell migration |
| CD44 | Cell surface glycoprotein that binds hyaluronan and other ECM components | Involved in cell migration, inflammation, and cancer stemness |
| HSPG2 | Perlecan, a heparan sulfate proteoglycan that binds growth factors and ECM | Regulates basement membrane function and angiogenesis |
| DCN | Decorin, a small leucine-rich proteoglycan that binds collagen | Modulates collagen fibrillogenesis and growth factor signaling |
| VGLL4 | Transcription cofactor that regulates ECM homeostasis | Targeting VGLL4 mitigates osteoarthritis in preclinical models |
How Is extracellular matrix binding Regulated?
Extracellular matrix binding is regulated at multiple levels, including protein expression, post-translational modifications, and the availability of binding partners. Calcium ions act as key regulators by inducing conformational changes that modulate binding affinity. Proteolytic cleavage of ECM proteins by matrix metalloproteinases can expose or destroy binding sites, thereby altering interactions. Additionally, cytokines such as interferon-gamma can bind to the ECM, affecting their bioavailability and signaling. The composition of the ECM itself is dynamic, and changes in matrix stiffness or composition can feedback to regulate binding interactions.
extracellular matrix binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ECM1 | Ovarian cancer metastasis | Knockout or overexpression in ovarian cancer cell lines; xenograft mouse models |
| VGLL4 | Osteoarthritis | Knockout mice or cartilage-specific overexpression; surgical induction of osteoarthritis |
| APOE | Cardiovascular disease, atherosclerosis | Apoe knockout mice; binding assays with biglycan |
| FN1 | Cancer, fibrosis | Fibronectin knockout fibroblasts; conditional knockout mice |
| ITGB1 | Cancer, developmental defects | Conditional knockout in specific tissues; knock-in of binding-deficient mutants |
Cancer and Metastasis
Altered extracellular matrix binding is a hallmark of cancer progression. ECM protein 1a (ECM1) remodels the tumor microenvironment and differentially regulates ovarian cancer metastasis, with high ECM1 expression associated with poor prognosis. Integrins and CD44, which bind ECM components, promote cancer cell survival, migration, and invasion. Targeting ECM-binding interactions is a promising therapeutic strategy, as demonstrated by studies showing that disrupting these interactions can inhibit metastasis.
Osteoarthritis
Osteoarthritis is characterized by degradation of the cartilage extracellular matrix. Targeting VGLL4 maintains ECM homeostasis and mitigates osteoarthritis in preclinical models, highlighting the importance of ECM-binding proteins in disease pathogenesis. Matrix metalloproteinases such as MMP2 and MMP9 degrade collagen and proteoglycans, leading to cartilage destruction. Modulating ECM binding could therefore be a therapeutic approach for osteoarthritis.
Cardiovascular Disease
Apolipoprotein E (APOE) binds to biglycan in the vascular extracellular matrix, and this interaction may influence its retention and anti-atherogenic properties. Dysregulated ECM binding in the vessel wall contributes to atherosclerosis and restenosis. Calcium-dependent ECM protein interactions also play a role in vascular calcification, a common complication of cardiovascular disease.
Infectious Diseases
Pathogens exploit ECM binding to colonize host tissues. Staphylococcus epidermidis expresses a giant extracellular matrix binding protein that binds surface-immobilized fibronectin, facilitating biofilm formation and infection. Understanding these interactions can inform the development of anti-adhesion therapies.
From extracellular matrix binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of ECM binding affect cell adhesion? | CRISPR knockout of the ECM-binding domain in the gene of interest, followed by adhesion assays |
| Does a point mutation in the binding domain alter affinity? | CRISPR point mutation (e.g., calcium-binding site) and surface plasmon resonance |
| Can a tagged version of the protein be used for imaging? | Knock-in of a fluorescent tag (e.g., GFP) at the endogenous locus |
| Does overexpression of the ECM-binding protein promote metastasis? | Overexpression in cancer cell lines and xenograft models |
| What is the role of calcium in ECM binding? | Point mutation of calcium-coordinating residues; calcium titration assays |
| Can we identify novel ECM-binding proteins? | CRISPR library screening with ECM-coated surfaces |
How to Study the extracellular matrix binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Surface plasmon resonance (SPR) | Binding affinity and kinetics | Quantify ECM-protein interactions and effects of mutations |
| ELISA | Binding specificity and concentration | Detect ECM-binding proteins in biological samples |
| Cell adhesion assay | Cell attachment to ECM | Assess functional impact of ECM-binding proteins |
| Immunofluorescence | Colocalization with ECM components | Visualize binding in tissues and cells |
| Mass spectrometry | Protein-protein interactions | Identify novel ECM-binding partners |
| CRISPR screening | Genes required for ECM binding | High-throughput discovery of regulators |
| Calcium titration assay | Calcium dependence of binding | Determine role of calcium in ECM interactions |
Biochemical Binding Assays
Surface plasmon resonance (SPR) and enzyme-linked immunosorbent assays (ELISA) are commonly used to measure the affinity and kinetics of ECM-protein interactions. These methods can quantify binding constants and assess the effects of mutations or calcium ions.
Cell Adhesion and Migration Assays
Cell adhesion assays on ECM-coated plates and transwell migration assays are used to evaluate the functional consequences of ECM binding. Knockout or knockdown of the binding protein can abolish adhesion, while rescue experiments can restore it.
Imaging and Colocalization
Immunofluorescence and live-cell imaging with fluorescently tagged proteins allow visualization of ECM binding in situ. Colocalization with ECM markers such as fibronectin or collagen confirms binding specificity.
Proteomics and Interactomics
Mass spectrometry-based proteomics can identify novel ECM-binding partners. Pull-down assays using recombinant ECM domains followed by LC-MS/MS reveal interaction networks.
How CRISPR Can Be Used to Study GO:0050840 extracellular matrix binding
Knockout
CRISPR knockout of genes encoding ECM-binding proteins or their binding domains can abolish specific interactions. For example, knocking out FN1 eliminates fibronectin-mediated adhesion and matrix assembly. Knockout models are essential for determining the necessity of a given ECM-binding protein in development and disease.
Point Mutation
Point mutations can be introduced to disrupt specific binding residues, such as calcium-coordinating aspartates or the RGD motif. These models help dissect the contribution of individual interactions without affecting protein expression or folding.
Knock-in
Knock-in of tagged versions (e.g., GFP, HA) or disease-associated mutations allows tracking of ECM-binding proteins in live cells and tissues. Knock-in of a binding-deficient mutant can serve as a negative control.
Overexpression
Overexpression of ECM-binding proteins in cell lines or transgenic animals can model gain-of-function effects, such as enhanced metastasis or matrix deposition. This approach is useful for studying the sufficiency of a protein in driving disease phenotypes.
How EDITGENE Supports extracellular matrix binding Research
Researchers studying extracellular matrix binding-related genes often need to determine whether a candidate gene is causally involved in a specific biological process or disease. This requires precise genetic manipulation to avoid confounding effects from compensatory mechanisms or off-target interactions. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate such investigations, from knockout to knock-in and high-throughput screening.
Contact EDITGENE today to design your custom CRISPR model for extracellular matrix binding research.
Frequently Asked Questions About extracellular matrix binding
What is GO:0050840 extracellular matrix binding?
GO:0050840 is a Gene Ontology molecular function term defined as binding to a component of the extracellular matrix. It encompasses interactions with proteins such as fibronectin, collagens, and proteoglycans.
What genes are involved in extracellular matrix binding?
Key genes include FN1 (fibronectin), BGN (biglycan), APOE (apolipoprotein E), COL1A1 (collagen type I), and ITGB1 (integrin beta-1), among many others.
How is extracellular matrix binding regulated?
It is regulated by calcium ions, proteolytic cleavage, post-translational modifications, and the availability of binding partners.
What diseases are associated with abnormal extracellular matrix binding?
Cancer metastasis, osteoarthritis, cardiovascular disease, and infectious diseases are linked to dysregulated ECM binding.
What methods are used to study extracellular matrix binding?
Common methods include surface plasmon resonance, cell adhesion assays, immunofluorescence, and mass spectrometry.
Can CRISPR be used to study extracellular matrix binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect ECM-binding protein functions.
What is the role of calcium in extracellular matrix binding?
Calcium ions often stabilize binding domains and induce conformational changes necessary for high-affinity interactions.
How does fibronectin contribute to extracellular matrix binding?
Fibronectin binds integrins and other ECM molecules, serving as a scaffold for matrix assembly and cell adhesion.
What is the clinical significance of apolipoprotein E binding to biglycan?
This interaction may retain apolipoprotein E in the vascular matrix, influencing its anti-atherogenic properties.
How can I create a knockout model for an ECM-binding gene?
EDITGENE provides custom CRISPR knockout services for ECM-binding genes in various cell types and animal models.
Conclusion
Extracellular matrix binding (GO:0050840) is a fundamental molecular function that underpins cell-ECM communication and tissue homeostasis. Its dysregulation is implicated in a wide range of diseases, from cancer to osteoarthritis, making it a critical area of research. Advances in CRISPR-based models and high-throughput screening are accelerating the discovery of new ECM-binding proteins and their therapeutic potential. EDITGENE offers comprehensive services to support these investigations, from gene knockout to bioinformatics analysis.
References
- 1. Kemna J et al.. 2023. IFNγ binding to extracellular matrix prevents fatal systemic toxicity.. Nat Immunol 24(3):414-422 PMID: 36732425
- 2. Suo J et al.. 2025. Targeting VGLL4 maintains extracellular matrix homeostasis and mitigates osteoarthritis in a preclinical model.. Nat Commun 16(1):9325 PMID: 41125571
- 3. Maurer P et al.. 1997. Structural and functional aspects of calcium binding in extracellular matrix proteins.. Matrix Biol 15(8-9):569-80; discussion 581 PMID: 9138289
- 4. Büttner H et al.. 2020. A Giant Extracellular Matrix Binding Protein of Staphylococcus epidermidis Binds Surface-Immobilized Fibronectin via a Novel Mechanism.. mBio 11(5) PMID: 33082256
- 5. Gopal S et al.. 2020. Calcium in Cell-Extracellular Matrix Interactions.. Adv Exp Med Biol 1131:1079-1102 PMID: 31646546
- 6. Yu Y et al.. 2024. Remodeling of tumor microenvironment by extracellular matrix protein 1a differentially regulates ovarian cancer metastasis.. Cancer Lett 596:217022 PMID: 38849014
- 7. Singh P et al.. 2010. Assembly of fibronectin extracellular matrix.. Annu Rev Cell Dev Biol 26:397-419 PMID: 20690820
- 8. Klezovitch O et al.. 2001. Domains of apolipoprotein E involved in the binding to the protein core of biglycan of the vascular extracellular matrix: potential relationship between retention and anti-atherogenic properties of this apolipoprotein.. Trends Cardiovasc Med 11(7):263-8 PMID: 11709279
